Pseudotyped Viruses for the Alphavirus Chikungunya Virus
© 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd..
Members of the genus Alphavirus are mostly mosquito-borne pathogens that cause disease in their vertebrate hosts. Chikungunya virus (CHIKV), which is one member of the genus Alphavirus [1], has been a major health problem in endemic areas since its re-emergence in 2006. CHIKV is transmitted to mammalian hosts by the Aedes mosquito, causing persistent debilitating symptoms in many cases. At present, there is no specific treatment or vaccine. Experiments involving live CHIKV need to be performed in BSL-3 facilities, which limits vaccine and drug research. The emergence of pseudotyped virus technology offered the potential for the development of a safe and effective evaluation method. In this chapter, we review the construction and application of pseudotyped CHIKVs, the findings from which have enhanced our understanding of CHIKV. This will, in turn, enable the exploration of promising therapeutic strategies in animal models, with the ultimate aim of developing effective treatments and vaccines against CHIKV and other related viruses.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1407 |
|---|---|
| Enthalten in: |
Advances in experimental medicine and biology - 1407(2023) vom: 15., Seite 299-312 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wu, Jiajing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chikungunya virus |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 20.03.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1007/978-981-99-0113-5_16 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354262378 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354262378 | ||
| 003 | DE-627 | ||
| 005 | 20231226061832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/978-981-99-0113-5_16 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1180.xml |
| 035 | |a (DE-627)NLM354262378 | ||
| 035 | |a (NLM)36920704 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wu, Jiajing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pseudotyped Viruses for the Alphavirus Chikungunya Virus |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 20.03.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. | ||
| 520 | |a Members of the genus Alphavirus are mostly mosquito-borne pathogens that cause disease in their vertebrate hosts. Chikungunya virus (CHIKV), which is one member of the genus Alphavirus [1], has been a major health problem in endemic areas since its re-emergence in 2006. CHIKV is transmitted to mammalian hosts by the Aedes mosquito, causing persistent debilitating symptoms in many cases. At present, there is no specific treatment or vaccine. Experiments involving live CHIKV need to be performed in BSL-3 facilities, which limits vaccine and drug research. The emergence of pseudotyped virus technology offered the potential for the development of a safe and effective evaluation method. In this chapter, we review the construction and application of pseudotyped CHIKVs, the findings from which have enhanced our understanding of CHIKV. This will, in turn, enable the exploration of promising therapeutic strategies in animal models, with the ultimate aim of developing effective treatments and vaccines against CHIKV and other related viruses | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Chikungunya virus | |
| 650 | 4 | |a Neutralization | |
| 650 | 4 | |a Pseudotyped virus | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Huang, Weijin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Youchun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in experimental medicine and biology |d 1971 |g 1407(2023) vom: 15., Seite 299-312 |w (DE-627)NLM000012157 |x 0065-2598 |7 nnns |
| 773 | 1 | 8 | |g volume:1407 |g year:2023 |g day:15 |g pages:299-312 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/978-981-99-0113-5_16 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1407 |j 2023 |b 15 |h 299-312 | ||